Compare Badger Meter Inc (BMI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Badger Meter Inc vs Summit Therapeutics Inc — how do they compare? Badger Meter Inc trades at $141.46 (market cap $4.13B), while Summit Therapeutics Inc trades at $15.56 (market cap $12.01B). The key difference: Summit Therapeutics Inc is far larger — about 2.9× Badger Meter Inc's market cap, and Badger Meter Inc pays a 1.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BMI | SMMT | |
|---|---|---|
Market Cap | $4.13B | $12.01B |
Sector | Technology | Health |
52-Week High | $245.81 | $29.32 |
52-Week Low | $113.41 | $13.05 |
Enterprise Value | $3.92B | $11.43B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $140.12, down 2.82% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $917M revenue and $142M net income for 2025, with strong profitability margins but recent earnings misses in Q4 2025 and Q1 2026. A securities class action lawsuit filed in July 2026 adds significant near-term uncertainty, though analyst consensus remains a Buy with a $144.60 price target.
The stock faces headwinds from legal risks and earnings volatility, but solid fundamentals and analyst support suggest potential recovery if legal concerns subside. Investors should weigh the high valuation multiples against operational strength and monitor lawsuit developments closely for directional cues.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
